Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: Results from the charisma trial

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Chen, J.
  • Bhatt, D. L.
  • Dunn, E. S.
  • Shi, C. X.
  • Caro, J. J.
  • Mahoney, E. M.
  • Gabriel, S.
  • Jackson, J. D.
  • Topol, Eric
  • Cohen, D. J.

publication date

  • 2009

journal

  • Value in Health  Journal

subject areas

  • Aged
  • Aspirin
  • Cardiovascular Diseases
  • Cost-Benefit Analysis
  • Databases, Factual
  • Drug Therapy, Combination
  • Female
  • Health Care Costs
  • Hospitalization
  • Humans
  • Life Expectancy
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Platelet Aggregation Inhibitors
  • Randomized Controlled Trials as Topic
  • Saskatchewan
  • Secondary Prevention
  • Survival Analysis
  • Ticlopidine
  • United States
scroll to property group menus

Research

keywords

  • aspirin
  • cardiovascular disease
  • clopidogrel
  • cost-effectiveness analysis
  • secondary prevention
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 1098-3015

Digital Object Identifier (DOI)

  • 10.1111/j.1524-4733.2009.00529.x

PubMed ID

  • 19490556
scroll to property group menus

Additional Document Info

start page

  • 872

end page

  • 879

volume

  • 12

issue

  • 6

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support